The rising prevalence of dementia in Australia means that general practitioners will have an increasingly important role in the timely and accurate assessment of this condition. Two tools that are commonly used for assessing dementia are the Mini-Mental State Examination and the Alzheimer's Disease Assessment Scale (Cognitive sub-scale). The utility of these tools is maximised by the inclusion of information from other relevant sources, such as the patient's carers, and from clinical evaluation of the patient. These tests are not as complete as neuropsychological assessments. Referring patients for a more detailed assessment is appropriate when the diagnosis of dementia is in doubt.
Introduction
The requirement that patients with Alzheimer's disease must be assessed before drugs such as donepezil can be supplied through the Pharmaceutical Benefits Scheme (PBS) has focused attention on psychological testing of cognitive status. As the prevalence of neurodegenerative conditions is increasing, early accurate diagnosis is important so that patients can be treated promptly or referred for further assessment as required. General practitioners can play a vital role in this assessment.
Assessment tools
Despite the many advances in our understanding of Alzheimer's disease, primary diagnosis still relies on the identification of cognitive decline. 
Problems with brief cognitive tests
Any brief screen or assessment of a complex behaviour such as cognition has limitations.
Authority prescriptions
The Pharmaceutical Benefits Scheme requires that the diagnosis of dementia must be confirmed by a specialist if donepezil, galantamine or rivastigmine is prescribed.
Applications for authority prescriptions must state the result of the baseline MMSE and, if this score is at least 25 points, the application must also include the result of the baseline ADAS-Cog. After six months repeat prescriptions will only be approved if the MMSE score has increased by two points, or, in cases where the baseline MMSE is at least 25 points, the ADAS-Cog has decreased by at least four points.
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Despite its widespread clinical use, and like all brief dementiascreening tests, the MMSE has been criticised 3 for:
■ being insensitive to patients with mild cognitive impairment ■ lacking diagnostic specificity ■ not taking into account levels of education, premorbid ability, and other patient variables such as visual problems or poor command of English.
Dementia may be missed in some patients, and other patients without dementia may be misclassified. A normal score on the MMSE does not necessarily exclude a brain abnormality or dementia.
There is also some uncertainty about the clinical relevance of The information that this website offers is extremely useful, but the burning question is -how is it being publicised? Ensuring target groups, especially senior editorial staff, are aware of the site is the only way for it to have an impact, but it is unclear from the site whether or how it is promoted. This is an important initiative, but it needs significant public exposure if it is to achieve its aim.
PBAC questions: update
In the December issue of Australian Prescriber PBAC has now relaxed the requirements for authority prescriptions for increased maximum quantities and repeats of some narcotic analgesics.
